BioSpaceOriginal article
Syndax ends fibrosis program for Niktimvo after mid-stage disappointment
Trial StartnegativeNiktimvoNegative
AI Analysis
Summary
Syndax Pharmaceuticals is discontinuing development of Niktimvo for idiopathic pulmonary fibrosis following mid-stage trial disappointment, while continuing efforts to expand the drug's label in chronic graft-versus-host disease where it was approved in 2024.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Syndax ending fibrosis program for Niktimvo after mid-stage trial disappointment
Importance:6/10
Sentiment:
-0.70
program terminationfibrosismid-stage datalabel expansionGVHD
Read the original article
Published by BioSpace on October 13, 2026 12:55 PM